Dr Reddy's Q2 profit falls 36% on lower lenalidomide sales in North America
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Dr Reddy's Laboratories reported a 36 per cent fall in consolidated net profit to Rs 925 crore for the second quarter of FY27.
- ✓The company said lower lenalidomide sales in North America hurt results.
- ✓Co-chairman G V Prasad said, "We continued to improve the overall health of our business."
Story at a Glance
- Category
- MARKET
- Reported By
- Business Standard
- Reading Speed
- 5 Minute(s)
- Market Focus
- India Economy
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) on Friday reported a year-on-year (Y-o-Y) decline of 36 per cent in consolidated net profit to Rs 925 crore in the second quarter of 2026-27 (FY27). Revenue also declined by 1.5 per cent to Rs 8,670.8 crore.
The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth.
On a sequential basis, consolidated net profit rose 109 per cent from Rs 443.5 crore in the first quarter of FY27, while revenue increased 7.4 per cent from Rs 8,070.5 crore. The first-quarter figures were weighed down by a Rs 239.7 crore provision for inventory and related costs associated with semaglutide's active pharmaceutical ingredient (API).
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Standard
Read the full, original unfiltered story directly on the publisher's portal.